[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"HealthPartners Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":361},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,44,72,103,133,155,175,204,231,255,281,305,329],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100347523","rehabilitation-following-reverse-total-shoulder-arthroplasty-100347523",false,"NCT03804853","Rehabilitation Following Reverse Total Shoulder Arthroplasty","Immediate Accelerated Shoulder Rehabilitation Versus a Standard Protocol Following Reverse Total Shoulder Arthroplasty: A Randomized Controlled Trial","RTSA","Inclusion Criteria:\n\n* \\> 55 years of age.\n* Candidate for a primary reverse total shoulder arthroplasty.\n* Capable of completing self-administered questionnaires.\n* Be willing and able to return for all study-related follow-up procedures.\n* Able and willing to give informed consent.\n* Proficient in the English language.\n\nExclusion Criteria:\n\nIn-Clinic:\n\n* Patients planning on undergoing a Primary Reverse Shoulder Total Arthroplasty due to proximal humeral fracture.\n* Previous shoulder surgery including previous total shoulder arthroplasty or reverse total shoulder arthroplasty or hemiarthroplasty, or instability repairs\n* Active bacterial infection of the shoulder.\n* Any concomitant shoulder procedure.\n* Additional ipsilateral or contralateral upper limb pathology that requires active treatment (i.e. surgery or brace).\n* Inflammatory arthropathy.\n* Diagnosed with Rheumatoid arthritis\n* Diagnosed with gout.\n* Subject is on chronic anticoagulation due to a bleeding disorder or has taken anticoagulants within 10 days prior to surgery.\n* Peripheral vascular disease or other vascular disorders that would impair healing.\n* Peripheral neuropathy or other neurological disorders that may impair the patient to ambulate.\n* Patient is on workers compensation.\n* Any condition requiring chemotherapy.\n* Active tobacco user or former tobacco user who is not free of using tobacco for 8 weeks.\n* Uncontrolled Diabetes Mellitus with an HbA1C \\> 7.5%.\n* Current drug or alcohol abuse.\n* Major medical illness (life expectancy less then 2 years or unacceptably high operative risk)\n* Suspicion of cervical radiculopathy or myelopathy.\n* Deltoid insufficiency on physical examination.\n\nIntra-operative:\n\n• Iatrogenic glenoid fracture\n\nPost-operative:\n\n* Neurological injury of the upper extremity.\n* Complications from Primary Reverse Shoulder Total Arthroplasty (i.e. post-operative infection, bleeding, hardware failure).","ALL","55 Years",{"count":20,"type":21},74,"ESTIMATED","INTERVENTIONAL",[24],"NA","Reverse total shoulder arthroplasty (RTSA) has been successful in patients with rotator cuff arthropathy, proximal humerus fractures, failed primary total shoulder arthroplasty or failed hemiarthroplasty, and massive irreparable rotator cuff tear. Patients who undergo an RTSA report pain relief and functional range of motion. It has been more than 20 years since the advent of the RTSA construct but an immediate post-operative rehabilitation with active shoulder range of motion has not been prospectively studied in comparison to the traditional post-operative rehabilitation highlighted by Boudreau et al.12 Investigators plan to prospectively follow our patients following RTSA undergoing an immediate active shoulder rehabilitation (IASR) vs traditional rehabilitation in a randomized controlled fashion. Investigators plan to document clinical outcomes, complications and cost effectiveness out to 1 year.\n\nThe study will hopefully fulfill the Triple Aim model for HealthPartners by improving the health of the population, improve the experience of each individual, and make healthcare affordable by decreasing the total cost of care.",[27],"Shoulder Osteoarthritis",[29,30],"Rehabilitiation","Reverse total shoulder","RECRUITING","2026-06-24",{"date":34,"type":35},"2026-06-26","ACTUAL",{"date":37,"type":35},"2018-12-12",{"date":39,"type":21},"2027-06-30",{"name":41,"class":42},"HealthPartners Institute","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100592266","acl-reconstruction-rehabilitation-with-exercise-and-psychological-support-100592266","NCT06991192","ACL Reconstruction Rehabilitation With Exercise and Psychological Support","ACLR-REPS","Inclusion Criteria:\n\n* Age 15 to 21 years at the time of surgery;\n* Pre-injury Tegner Activity Rating60 ≥ 5 (5=recreational sports, 10=elite sports);\n* Sports participation at least 100 hours\u002Fyear prior to injury;\n* Intent to resume a pre-injury sport that requires cutting, jumping, or pivoting;\n* ACL reconstruction performed ≤ 6 months from injury;\n* ACL reconstruction performed with bone-patellar tendon-bone autograft or quadriceps tendon autograft; and\n* Able to complete rehabilitation at one of the 4 participating TRIA locations.\n\nExclusion Criteria:\n\n* Previous ACL injury or surgery to either limb;\n* Concomitant ligamentous injury \\> Grade II or requiring surgery; and\n* Surgical procedure to articular cartilage requiring non-weight-bearing after surgery.","15 Years","21 Years",{"count":54,"type":21},60,[24],"The purpose of this study is to examine ACLR Rehabilitation with Exercise and Psychological Support (REPS), comparing two approaches for providing psychological support along with exercise during ACL reconstruction rehabilitation. In one group, physical therapists have received training that may boost emotional support during rehabilitation. In the other group, physical therapists will not have the training. Both groups will get similar exercises and participate in the same testing. Both groups will also watch short videos during rehabilitation that are specific to their group. Participants will not know to which group they are assigned until the end of the study. Participation will attend a total of four study visits over the course of 6 months, including 1 visit before the surgery and 3 visits during follow-up.",[58],"Anterior Cruciate Ligament Reconstruction Rehabilitation",[60,61,62,63],"ACL Reconstruction","Anterior Cruciate Ligament","Rehabilitation","Psychological","2026-05-01",{"date":66,"type":35},"2026-05-05",{"date":68,"type":35},"2025-05-01",{"date":70,"type":21},"2027-08-31",{"name":41,"class":42},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":91,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100620230","phase-2-axelopran-for-advanced-cancer-in-patients-receiving-opioids-100620230","NCT07354919","Axelopran for Advanced Cancer in Patients Receiving Opioids","A Phase II Trial of Cancer Response Using Axelopran in Patients With Advanced Cancers on Opioids (AxeCan)","AxeCan","Inclusion Criteria:\n\n1. Adults (aged 18 or more at enrollment).\n2. Histologically or cytologically proven cancer of the prostate (carcinoma), breast (carcinoma), pancreas (carcinoma), and lung (non-small cell lung carcinoma (NSCLC)) that has relapsed or progressed on or after a standard systemic treatment that has included cytotoxic chemotherapy.\n3. Advanced stage (locally advanced or metastatic) with no definitive plans for curative-intent therapy.\n4. A minimum life expectancy of at least 2 months at the time of the screening visit.\n5. Current use of an opioid medication with an average of 5mg OME\u002Fday over the past 3 days.\n6. At least one measurable lesion meeting RECIST v1.1 criteria.\n7. At least 2 weeks since last cancer-directed therapy:\n\n   1. NSCLC and pancreatic cancer must have received at least one line of systemic cytotoxic chemotherapy (+\u002F- immune checkpoint inhibitor) in the locally advanced\u002Fmetastatic setting.\n   2. Breast cancer must be considered refractory to hormone therapy (i.e., progressed on standard estrogen blocking therapy) or hormone negative (i.e., estrogen and progesterone-receptor negative) and have received at least one line of systemic cytotoxic chemotherapy in the locally advanced\u002Fmetastatic setting.\n   3. Prostate cancer must be considered metastatic castrate-resistant prostate cancer (mCRPC) and have progressed on at least one androgen receptor pathway inhibitor (ARPI) and docetaxel. Docetaxel could be given in the metastatic castrate-sensitive setting, and\u002For later in the mCRPC setting. Baseline testosterone level must be \\\u003C50 ng\u002FdL and surgical or ongoing medical castration must be maintained throughout the duration of the study.\n8. Patients must a) have relapsed or progressed on or after all standard therapy, b) be intolerant to standard therapy, c) not have standard therapy available that confers a significant clinical benefit, d) decline other standard therapy or agree with treating oncologist that a period of active surveillance off therapy is reasonable.\n9. Clinician and patient are willing to attempt a delay in next line of systemic cancer therapy (if available) until day 43 to assess change in cancer status on repeat imaging. Clinician can move to next line of therapy at any time if a patient's clinical course changes and urgent new treatment is required. Patients will be allowed to remain on axelopran if that occurs.\n\n   a) Planned palliative radiation therapy should be completed prior to study enrollment. Palliative radiation done during the primary study period would be considered next line of cancer therapy.\n10. Must be willing to report baseline and required patient-reported outcomes and report daily bowel movement frequency for monitoring stool changes.\n11. For a female subject of childbearing potential, must have documentation of a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1. All women are considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 2 years) or documented to be surgically sterile (bilateral tubal ligation or hysterectomy).\n12. Sexually active subjects must use a highly effective method of contraception during the study and for at least 90 days after completion of study drug dosing.\n\n    1. A highly effective method of birth control is defined as one that results in a low failure rate (i.e., \\\u003C 1% per year) when used consistently and correctly, such as condom + diaphragm, condom + spermicide, diaphragm + spermicide, or intrauterine device (IUD) with documented failure rate of \\\u003C 1% per year, or oral\u002Finjectable\u002Fimplanted hormonal contraceptives used in combination with an additional barrier method.\n    2. Males should refrain from donating sperm during the study and for 90 days after completion of study drug.\n\nExclusion Criteria:\n\n1. Any previous gastrointestinal surgery, except uncomplicated appendectomy or cholecystectomy.\n2. Any of the included cancer cohorts where active malignancy causes direct extension\u002Finvasion of the GI tract from local spread or distant metastasis.\n3. Current, active, untreated brain metastases.\n4. History of fecal incontinence\u002Fimpaction; irritable bowel syndrome; inflammatory bowel disease; intestinal obstruction; GI or pelvic disorders known to affect bowel transit, produce GI obstruction, or contribute to bowel dysfunction; fecal impaction requiring medical intervention within 1 month of enrollment.\n5. Subject is unable to eat, drink, take, or hold down oral medications.\n6. Use of buprenorphine, alvimopan, naltrexone, methylnaltrexone, naloxone, lubiprostone, linaclotide, or tapentadol therapy within 14 days before enrollment and inability or unwillingness to discontinue use until the end of the study.\n7. Receipt of strong inhibitors of CYP3A4 (e.g., antifungal azoles, grapefruit juice) or strong inducers of CYP3A4 (e.g., rifampin or carbamazepine), including any herbal medications such as St. John's Wort, within the last 14 days or 5 half-lives, whichever is longer, prior to study drug administration.\n8. Receipt of inhibitors of p-glycoprotein (P-gp) within the last 14 days prior to study drug administration.\n9. Receipt of anti-VEGF therapies (i.e. bevacizumab) within the last 30 days prior to study drug administration.\n10. Subjects with clinically significant abnormal ECG at screening or before randomization in the opinion of the Investigator, or a QTc \\> 470 msec (per Fridericia's correction).\n11. Presence of unstable diseases, in the opinion of the Investigator, such as cardiovascular (e.g., acute myocardial infarction or acute coronary syndrome \\\u003C 3 month history), respiratory (e.g., requires oxygen), gastrointestinal (e.g., symptomatic diverticulitis, irritable bowel syndrome \\[IBS\\], etc.), endocrine (e.g., uncontrolled diabetes or A1c \\> 10%), hematologic, neurologic, psychiatric (e.g., schizophrenia, unstable anxiety disorder, acute psychosis, depression with suicidal ideation, etc.), or any other significant conditions that may affect subject assessment.\n12. Any other condition which, in the opinion of the investigator, could confound or interfere with evaluation of safety, efficacy, or tolerability of the investigational drug, or prevent compliance with the study protocol.\n13. Women who are pregnant, breastfeeding, or of childbearing potential without the use of birth control.","18 Years",{"count":82,"type":21},34,[84],"PHASE2","The primary objective of this single arm, open label, phase II trial is to determine if axelopran use impacts cancer control in patients with advanced cancers of the lung, breast, pancreas, and prostate. The primary study period for assessing the primary aim is through day 43 (6 weeks). The main questions it aims to answer are:\n\n* Does axelopran show a signal for efficacy in slowing tumor progression?\n* Is axelopran safe and tolerable for long-term use in this patient population?\n* Does axelopran show a signal for efficacy in improving bowel function and quality of life?\n* Does axelopran show a signal for efficacy in reducing systemic inflammation, cachexia, and prognostic serum biomarkers of inflammation?\n\nPatients will take axelopran as monotherapy after relapse or progression on or after standard systemic therapy. Clinician and patient must be willing to attempt a delay in next line of systemic cancer therapy (if available) until day 43 to assess change in cancer status on repeat imaging. Clinician can move to the next line of therapy whenever deemed clinically necessary.\n\nParticipants will:\n\n* take oral axelopran capsules daily for up to 1 year, or longer if deriving benefit\n* attend 10 in-person study visits, each lasting approximately 1-2 hours\n* complete study procedures including but not limited to imaging exams, blood draws, electronic health surveys, and physical assessments",[87,88,89,90],"Breast Cancer","Lung Cancer","Pancreas Cancer","Prostate Cancer",[92,93,94],"cancer","axelopran","opioids","2026-04-29",{"date":66,"type":35},{"date":98,"type":35},"2026-04-27",{"date":100,"type":21},"2028-11-01",{"name":41,"class":42},2,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":43},"100622471","phase-1-safety-and-feasibility-of-intranasal-insulin-in-patients-with-spinal-cord-injury-100622471","NCT07384052","Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury","INI-SCI","Inclusion Criteria:\n\n1. Subject is ≥18 and \\\u003C85 years of age\n2. Subject has sustained a traumatic or non-traumatic spinal cord injury with American Spinal Injury Association (ASIA) rating A, B, C or D, complete or incomplete\n3. Subject sustained spinal cord injury at least 4 months before baseline visit\n4. Female subjects must have either: (1) a negative pregnancy test at the screening and treatment visits OR (2) be at least 2 years post-menopausal \u002F surgically sterile\n5. The subject must be proficient in English in order to comply with instructions and measures for the study\n6. Subject is able to prepare and administer the study drug as outlined in the protocol or has a carer who is available to do so for the duration of the study\n7. Subject can provide written informed consent\n8. Subject has been on a stable regimen of medications for at least 30 days from baseline visit\n\nExclusion Criteria:\n\n1. Subject is dependent on a ventilator or has a patent tracheostomy site\n2. Subject has recent history (within past 6 months) of recurrent autonomic dysreflexia, defined as a sudden rise in systolic BP greater than 20 mmHg or diastolic BP greater than 10 mmHg without rise in heart rate and accompanied by symptoms such as headache, facial flushing, sweating, nasal congestion, or blurry vision\n3. Subject has medical history and\u002For clinically determined disorders: chronic sinusitis, previous nasal and\u002For oto-pharyngeal surgery and severe deviated septum and\u002For other anomalies\n4. Subject has history of any of the following: active and significant central nervous system, psychiatric illness, pulmonary, or cardiovascular disorders or any other clinically relevant abnormality that inclusion would pose a safety risk to the subject as determined by investigator\n5. Subject has participated in a clinical trial investigation within 3 months of this study\n6. Subject has a history of allergy, hypersensitivity, or other significant adverse reaction to insulin\n7. Subject is taking insulin for Type I or Type II diabetes\n8. Subject is pregnant or breast feeding\n9. Any other clinically relevant finding that would pose a safety risk to the subject as determined by the investigator","84 Years",{"count":112,"type":21},12,[114],"PHASE1","The purpose of this study is to find out whether insulin, a drug approved by the FDA for the treatment of diabetes mellitus, is safe when administered as a nasal spray (intranasally) to people who have experienced a spinal cord injury. While insulin nasal spray has been shown to be safe in many patient populations, it has not yet been studied in people with spinal cord injury. This study would be the first step to developing insulin nasal spray as a treatment for spinal cord injury in the future.\n\nThis study is recruiting up to 12 individuals who have experienced a spinal cord injury at least 4 months ago to administer either 76 IU insulin nasal spray or a placebo (inactive nasal spray) at home every day for up to 24 days. Participants will be asked questions about their health and symptoms related their spinal cord injury, and will have their blood collected throughout the study. Participants who are unable to administer the medication independently must have a study partner in order to participate.",[117],"Spinal Cord Injury",[119,120,121,122,117,123,124],"Insulin","Intranasal","Safety","Feasibility","SCI","INI","2026-03-20",{"date":127,"type":35},"2026-03-23",{"date":129,"type":35},"2026-02-20",{"date":131,"type":21},"2026-09",{"name":41,"class":42},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":140,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":154,"locationsCount":43},"100602716","an-insole-and-ankle-device-for-monitoring-cognitive-decline-in-individuals-at-risk-for-alzheimers-disease-andor-alzheimers-disease-related-dementias-adadrd-100602716","NCT07127133","An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and\u002For Alzheimer's Disease Related Dementias (AD\u002FADRD)","A Gait and Path Tortuosity System for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and\u002For Alzheimer's Disease Related Dementias (AD\u002FADRD)","Inclusion Criteria:\n\n* Age 55 or older\n* Ability to ambulate without the use of an assistive device. For this study, we will assume participants are ambulatory if they can complete the functional outcome measures (i.e., TUG) without the use of an assistive device\n* Ability to understand and provide informed consent, or has a legally authorized representative (LAR) to provide consent on their behalf\n* Ability to don and doff the insole and leg module independently or have assistance for the duration of the study\n\nExclusion Criteria:\n\n* Non-English Speaking\n* Use of ankle-foot orthosis for ambulation that prevents use of the system\n* Self-reported acute thrombophlebitis including deep vein thrombosis\n* Untreated lymphedema or lesion of any kind, swelling, infection, inflamed area of skin or eruptions on or near product use (foot and ankle)\n* Untreated fractures in the foot and ankle\n* Any other significant medical condition that may affect participation or performance in the study, as determined by investigators",true,{"count":142,"type":21},150,[24],"This study tests an innovative system and service for collecting objective, consistent, and in-community gait parameters suitable for use as AD\u002FADRD biomarkers. The system is designed to be affordable, scalable, and practical for longitudinal, unsupervised, in-community use by older adults, including those with dementia symptoms. This study will be performed in two parts and involves collecting gait data from participants using the leg module and insole device either (1) for several hours in a lab setting (in-lab testing) or (2) within their home and community for 1 week (in-community testing). Thirty people who are healthy, have mild cognitive impairment, or who have Alzheimer's disease or related dementia will be recruited to participate in the in-lab testing, in which they will perform walking tasks and cognitive testing for several hours within a lab environment. After completion of in-lab testing, 120 individuals who are healthy, have mild cognitive impairment, or who have Alzheimer's disease or related dementia will be recruited to participate in the in-community testing, in which they will wear the insole and ankle device within their community for 1-week for collection of gait data in real world settings.",[146,147],"Mild Cognitive Impairment (MCI)","Dementia","NOT_YET_RECRUITING",{"date":150,"type":35},"2026-03-24",{"date":152,"type":21},"2026-08-01",{"date":70,"type":21},{"name":41,"class":42},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":43},"100553834","light-vs-moderate-intensity-exercise-in-individuals-with-myasthenia-gravis-100553834","NCT06491238","Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis","MG-Ex","Inclusion Criteria:\n\n* Ability to provide and provision of signed and dated informed consent form.\n* Age 18-80\n* Diagnosis of generalized MG.\n* On a stable MG prescription medication regimen for the last 3 months.\n\nExclusion Criteria:\n\n* Non-English speaking\n* Regular exercise participation within the month prior to study enrollment or any outside exercise participation during the study intervention period.\n* Significant cognitive impairment of any etiology that would impact study participation.\n* History of heart failure, chronic lung disease, angina or any other condition that causes unreasonable shortness of breath on exertion.\n* History of any serious neurological, psychiatric, or substance use disorders that would impact study participation.\n* Women who are currently pregnant or planning to become pregnant during the study.\n* Any other medical conditions that could affect their ability to participate in exercise for the study duration (as determined by study investigators).\n* Active participation or past participation ≤3 months in any other interventional research study.\n* Unwilling to participate in all study related activities.","80 Years",{"count":164,"type":21},20,[24],"The overall purpose of this pilot study is to examine the feasibility, acceptability, and tolerability of light and moderate intensity exercise in adults with MGeffect of light vs. moderate intensity exercise on health outcomes. Participants will be enrolled into the NeuroWell exercise program, which is geared toward individuals with neurological disorders or injuries and led by Certified Exercise Physiologists (CEPs) at the HealthPartners Neuroscience Center. A total of 20 people with MG will be enrolled in this study and participate in a small group exercise program 3 times a week for 12 weeks. Participants will be randomized into two exercise groups: 1) Light intensity or 2) Moderate intensity. We hypothesize that light and moderate intensity exercise will be feasible, acceptable, and tolerable in adults with MG and that individuals in the light intensity exercise group will be able to achieve the same improvement in health outcomes as the moderate intensity group.",[168],"Myasthenia Gravis",{"date":127,"type":35},{"date":171,"type":35},"2024-09-16",{"date":173,"type":21},"2026-12",{"name":41,"class":42},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":191,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":43},"100617944","phase-2-reducing-risk-of-diabetic-ketoacidosis-in-type-1-diabetes-and-kidney-disease-using-continuous-ketone-monitoring-100617944","NCT07325201","Reducing Risk of Diabetic Ketoacidosis in Type 1 Diabetes and Kidney Disease Using Continuous Ketone Monitoring","Mitigating Diabetic Ketoacidosis in People With T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation Into an Enhanced Glucose Ketone Report","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form.\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Males and females; Ages 18-75.\n* Diagnosis of type 1 diabetes, based on a clinical diagnosis with onset at least 3 months prior to screening.\n* Using an automated insulin delivery system (AID) or multiple daily injections (MDI), (defined by use of rapid analogue with meals and approved long-acting analogue (e.g. detemir or glargine)).\n* Most recent eGFR ≥30 (and within prior 12 months).\n* HbA1c \\\u003C10%. 8) Have had ≥1 primary or specialty ambulatory visit(s) in the past year in the HealthPartners care system.\n* Have never been prescribed SGLT2i medications.\n* Must be willing and able to wear a CGM\u002FCKM device and willing to follow the study protocol.\n* Must be able to read and speak English.\n* Use of adequate contraception for the duration of the study be the women of childbearing potential.\n* Access to necessary resources for participating in a technology-based intervention (i.e., computer, smartphone, internet access).\n\nExclusion Criteria:\n\n* Pregnancy, lactation, planning to become pregnant or unwillingness to be on contraception during the trial.\n* Any form of diabetes other than T1D.\n* Any history of use of sodium-glucose cotransporter inhibitors and use of other non-insulin glucose lowering medication within the last 6 months.\n* Chronic systemic corticosteroids (\\>4 consecutive weeks) within 6 months before screening or planned use during the study period.\n* History of diabetic ketoacidosis within 3 months of screening or 2 or more episodes of DKA within the last year.\n* History of multiple (≥ 3 infections) genital mycotic infections within 6 months of screening.\n* Hypotension at screening as defined as, systolic blood pressure \\\u003C 90 and diastolic blood pressure \\\u003C 60 with symptoms of low blood pressure (confusion, dizziness, lightheadedness, fainting, heart palpitations).\n* History of a level 3 hypoglycemic event (as defined by ADA criteria) within 3 months of screening.\n* Recent myocardial infarction, stroke, hospitalization for unstable angina or heart failure within 3 months prior to screening.\n* New York Heart Association Class IV heart failure.\n* CKD-EPI estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m2.\n* Impairment of systems and organs that may increase their risk of participating in the intervention study or compromise the results (for example: end stage kidney disease, active liver dysfunction, gastroparesis, anemia, organ transplant).\n* Active Hepatitis B or C, or tuberculosis.\n* Abnormal liver function at screening defined as any of the following: aspartate aminotransferase (AST) \\>2X upper limit of the normal reference range (ULN), ALT \\>2X ULN, serum total bilirubin (TB) \\>1.5X ULN.\n* History of severe acquired immune deficiency syndrome or human immunodeficiency virus (HIV) infection or severely immunocompromised status, in the opinion of the investigator, including, but not limited to patients who have undergone organ or bone marrow transplantation. HIV positive patients who are on stable immunosuppressive therapy and have undetectable viral load may be eligible for inclusion in the study, subject to the investigator's discretion.\n* Current or past history of decompensated cirrhosis (defined as variceal bleeding, ascites or hepatic encephalopathy), and\u002For known diagnosis of cirrhosis.\n* Cancer treatment (excluding non-melanoma skin cancer treated by excision, carcinoma in situ of the cervix or uterus, ductal breast cancer in situ, resected non-metastatic breast or prostate cancer) within one year of screening.\n* History of kidney transplant.\n* CKD from a known cause other than T1D.\n* A diagnosed eating disorder.\n* BMI \\\u003C22.\n* Adherence to a very low CHO or ketogenic diet.\n* A foot amputation.\n* Non-healing wounds of extremities.\n* Inability to perform the study follow up\u002F unwilling to wear the investigational device.\n* Heavy alcohol use (for men, ≥5 drinks on any day or ≥15 drinks per week; for women, ≥4 drinks on any day or ≥8 drinks per week) at screening, history of alcohol use disorder or binge drinking.\n* Participation in another treatment or intervention study within the past six weeks.\n* Any condition or factor that would compromise the participant's safety or conduct of the study (for example: cognitive impairment, bipolar disorder, or eating disorder) or any other reason the PI deems that the patient should not be included.","75 Years",{"count":184,"type":21},80,[84],"The goal of this clinical trial is to develop and evaluate a novel diabetes ketoacidosis risk mitigation strategy to support the safe use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy in participants with type 1 diabetes (T1D) and mild to moderate chronic kidney disease (CKD). The main objectives of this study are to:\n\n1. Evaluate how ketone metrics differ between participants with mild to moderate chronic kidney disease and those with normal renal function in three time periods.\n2. Identify potentially modifiable ketosis risk factors.\n3. Use continuous glucose monitoring (CGM) and continuous ketone monitoring (CKM) data prior to and following treatment to determine ketosis risk factors and gain knowledge to further refine reporting of risk factors.\n4. Gather information on how participants and clinicians like and use the CGM\u002FCKM reports.\n\nParticipants will be asked to:\n\n* Meet with study investigators to determine if they are eligible\n* Sign written informed consent\n* Take a pregnancy test, if applicable\n* Have blood taken to assess kidney function and hemoglobin A1c\n* Take the study medication, following the study team instructions\n* Wear the study provided sensor throughout participation.\n* Complete 5 in person visits, and 11 phone check ins over a nine-month period\n* Provide feedback on the usefulness of CGM\u002FCKM reports",[188,189,190],"Type 1 Diabetes Mellitus","Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM)","Chronic Kidney Disease",[192,190,193,194,195],"Type 1 Diabetes","Continuous Glucose Monitoring","Diabetic Ketoacidosis","Continuous Ketone Monitoring","2026-02-02",{"date":198,"type":35},"2026-02-04",{"date":200,"type":21},"2026-06",{"date":202,"type":21},"2028-08",{"name":41,"class":42},{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":140,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":211,"targetDuration":213,"studyType":214,"phases":4,"briefSummary":215,"conditions":216,"keywords":219,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":43},"100610418","cannabis-use-registry-to-improve-overall-understanding-of-symptoms-curious-100610418","NCT07227324","Cannabis Use Registry to Improve Overall Understanding of Symptoms (CURIOUS)","CURIOUS","Inclusion Criteria:\n\n* any adult aged 18 or older who is diagnosed with cancer and using cannabis",{"count":212,"type":21},1000,"1 Year","OBSERVATIONAL","Through partnership with Ontracka, the HealthPartners Institute Cancer Research Center created a secure and compliant app-based technology with the ability to seamlessly collect patient-level data on symptoms, cannabis use, real-time response to cannabis consumption, and patient-reported changes in supportive care medications such as opioids and antiemetics. By joining this registry, patients will have access to expert cannabis education, dosing recommendations, and easy symptom tracking. Patients with cancer and their oncology clinicians can utilize this reliable, cancer-specific data to help them make informed decisions together about how cannabis could be incorporated into a treatment plan. To learn more and sign up, visit https:\u002F\u002Fstudy.ontracka.com\u002Fcannabiscurious",[217,218],"Cannabis Use","Cancer",[220,92,221,222],"cannabis","symptom management","education","2025-11-10",{"date":225,"type":35},"2025-11-12",{"date":227,"type":35},"2025-08-26",{"date":229,"type":21},"2028-04",{"name":41,"class":42},{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":244,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":43},"100556384","novel-post-surgical-incision-management-to-prevent-ostomy-complications-100556384","NCT06524401","Novel Post-Surgical Incision Management to Prevent Ostomy Complications","Inclusion Criteria:\n\n* Participant is greater than 18 years of age, inclusive\n* Participant is undergoing ileostomy surgery or,\n* has an enterocutaneous fistula with output over 500cc in 24 hours\n* Participants stoma will have a maximum diameter of 1.5 inches based on measurements from the Investigator or Sponsor.\n* Area around the stoma must have no injury through the dermis (i.e., intact skin)\n* Participant is willing and able to comply with all protocol-specified requirements\n* Participant is capable of reading and understanding English and will provide written informed consent to participate.\n\nExclusion Criteria:\n\n* Unable\u002Funwilling to attend the follow-up appointments\n* Participant has a life expectancy \\\u003C 30 days.\n* Participant has a stature too small for use of the Limpet in the opinion of the Investigator or Sponsor.\n* Participant has an enteroatmospheric fistula (enteric fistula to an open wound)\n* Participant is scheduling\u002Fplanning concurrent chemotherapy or other radiation treatment during the study follow-up period\n* Participant has a history of sensitivity or allergy to hydrocolloids or other materials in the Limpet device.\n* Participant is pregnant or planning to become pregnant (verbal report).\n* Participant is unable or unwilling to provide informed consent.\n* Participant is currently participating in an investigational drug or another device study that clinically interferes with the current study endpoints.\n* Participant has any other disease or medical condition that, in the opinion of the Investigator or Sponsor, could endanger the participant, interfere with the evaluation of the study device's efficacy or safety, or compromise the participant's ability to comply with\u002Fcomplete the study.",{"count":238,"type":21},92,[24],"The goal of this clinical trial is to evaluate the safety and effectiveness of the Limpet, as compared to standard of care ostomy pouches, in reducing complications for ostomy and fistula patients. Secondary objectives include evaluating dressing leak rates and causes of complications (e.g., edema, tissue oxygen saturation, and poor stoma eversion). The main questions it aims to answer are:\n\nPrimary Hypothesis 1: Peristomal Skin Complications will decrease\n\nPrimary Hypothesis 2: Dressing Leak Rates will decrease\n\nParticipants will:\n\n* Receive either the Limpet device or standard of care adhesive ostomy pouch dressing\n* Return every 7 days for study visits for 30 days to receive device replacement, wound imaging, blood tests, and quality of life surveys.",[242,243],"Ostomy","Enterocutaneous Fistula",[245,246],"Stoma","Ileostomy","2025-09-24",{"date":249,"type":35},"2025-09-25",{"date":251,"type":35},"2024-11-18",{"date":253,"type":21},"2029-03",{"name":41,"class":42},{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":269,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":43},"100602198","irrigating-vs-traditional-negative-pressure-wound-therapy-to-treat-necrotizing-soft-tissue-infections-100602198","NCT07120386","Irrigating vs Traditional Negative Pressure Wound Therapy to Treat Necrotizing Soft Tissue Infections","Instillation vs Traditional Negative Pressure Wound Therapy: A Pilot Randomized Controlled Trial for Necrotizing Soft Tissue Infections (NPWTi-NSTI Trial)","NPWT-NSTI","Inclusion Criteria:\n\n* Clinical suspicion for Necrotizing Soft Tissue Infection (NSTI) necessitating emergent operative intervention\n* Age \\>\u002F=18 years old\n* Planned application of a negative pressure wound dressing\n\nExclusion Criteria:\n\n* Patients who have a wound that does not allow for a wound vac\n* Patients receiving acute treatment for a NSTI at another institution\n* Incarcerated patients\n* Patients who do not survive to wound closure\u002Fcoverage\n* Patients \\\u003C18 years old",{"count":264,"type":21},30,[24],"Necrotizing Soft Tissue Infections (NSTIs) are rapidly progressing infections that have a high morbidity and mortality, with the greatest morbidity related to managing the large wounds required to treat these patients. Initial treatment requires wide surgical removal of infected tissue and optimal management is essential to reducing morbidity in these patients. Negative pressure wound therapy (NPWT) is a widely used technology that has revolutionized wound management. NPWT is utilized across the spectrum of acute wounds, including routine postoperative incision management, traumatic wounds, and wounds related to surgical debridement of NSTIs which are frequently some of the most complicated of wounds encountered. Most NSTI cases at Regions Hospital currently utilize negative pressure wound therapy with instillation (NPWTi) where the wound is irrigated to clean out debris. Currently, there is a paucity of data comparing traditional NPWT and NPWTi and the choice of which device to use is left to surgeon discretion. This study is a first step at identifying the effects of NPWTi compared to NPWT alone on the care of NSTI patients. If the theoretical benefits of NPWTi over NPWT translate to practice, those treated with NPWTi would be expected to have a reduced rate of hospital readmission after their index hospitalization in addition to shorter time to definitive closure\u002Fcoverage. This is a pilot study to assess the feasibility of enrolling patients with NSTIs in a randomized controlled trial to assess outcomes between the two devices.",[268],"Necrotizing Soft Tissue Infections",[270,271,272],"Negative pressure wound therapy","NPWT","NPWTi","2025-09-16",{"date":275,"type":35},"2025-09-17",{"date":277,"type":35},"2025-08-01",{"date":279,"type":21},"2026-10",{"name":41,"class":42},{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":22,"phases":290,"briefSummary":291,"conditions":292,"keywords":295,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":302,"leadSponsor":304,"locationsCount":43},"100570002","the-effect-of-the-safe-and-sound-protocol-on-depression-and-anxiety-symptoms-100570002","NCT06701578","The Effect of the Safe and Sound Protocol on Depression and Anxiety Symptoms","SSP","Inclusion Criteria:\n\n* Client of DayBridge\n* 18 years old or older\n* Meet the DMS-V diagnostic criteria of Major Depressive Disorder and\u002For Generalized Anxiety Disorder\n\nExclusion Criteria:\n\n* Previous participation in the SSP\n* Self-reported hearing loss",{"count":289,"type":21},120,[24],"The goal of this study is to determine if a developed protocol involving modulated auditory stimulation is better than non-modulated auditory stimulation in reducing anxiety and depression in human subjects.",[293,294],"Anxiety","Depression",[296,297],"auditory","sound","2025-07-25",{"date":300,"type":35},"2025-07-28",{"date":200,"type":21},{"date":303,"type":21},"2027-06",{"name":41,"class":42},{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":22,"phases":315,"briefSummary":316,"conditions":317,"keywords":321,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":327,"leadSponsor":328,"locationsCount":43},"100562612","phase-2-medical-cannabis-in-patients-with-advanced-pancreatic-and-colorectal-cancer-100562612","NCT06605430","Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer","A Randomized Phase II Trial of Medical Cannabis to Reduce Symptom Burden in Patients With Advanced Pancreatic and Colorectal Cancer (CanPan-C)","CanPan-C","Inclusion Criteria\n\n1. Adults (aged 18 or more at enrollment)\n2. Histologically or cytologically proven pancreatic or colorectal cancer. Histologies may include listing of adenocarcinoma, poorly differentiated carcinoma, or other pathology terms that treating oncologist would consider managing per usual standard of care of pancreas and colorectal adenocarcinoma. Neuroendocrine tumors are excluded in both cancer types.\n3. Advanced stage (locally advanced or metastatic) pancreatic or colorectal cancer with no definitive plans for curative surgery in the next 3 months\n4. Self-report of experiencing nausea, vomiting, anorexia, cachexia (wasting), or pain at least once in the 14 days prior to randomization\n5. Plan to initiate or initiated within the past 2 weeks standard-of-care systemic chemotherapy (any regimen that does not include immunotherapy) at a participating institution with no prior systemic therapy in the prior 3 months (prior adjuvant or neoadjuvant chemotherapy is allowed as long as it was \\>3 months prior to randomization)\n6. Must be a resident of Minnesota\n7. Must be willing to be registered in the Minnesota Medical Cannabis Program and follow all rules and requirements of the state program\n8. Must be willing to report baseline and required patient-reported outcomes\n\nExclusion Criteria\n\n1. Self-reported regular use (using 10 or more days in the 30 days prior to randomization) of a THC containing cannabinoid product\n2. Patients with a history of intolerance or hypersensitivity to cannabis (i.e., cannabis hyperemesis)\n3. Patients with Alzheimer's dementia, active epilepsy, or history of traumatic brain injury\n4. Patients with known active or untreated brain metastases. A brain MRI is not required during the screening period.\n5. Patients initiating or receiving immunotherapy, a chemotherapy-immunotherapy combination, or non-standard cytotoxic chemotherapy (including patients enrolled\u002F enrolling in trials of investigational cancer-directed treatments)\n6. Women who are pregnant, breastfeeding or of childbearing potential without the use of birth control\n7. Uncontrolled acute or chronic medical conditions, psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for enrollment in this study\n8. Has any condition that in the opinion of the investigator might jeopardize the safety of the subject or interfere with protocol compliance",{"count":314,"type":21},64,[84],"Many patients with advanced pancreatic cancer and colorectal cancer experience burdensome and difficult-to-treat symptoms. The impact of multiple symptoms (called \"symptom burden\") can negatively affect a patient's quality of life, decrease their ability to tolerate cancer treatments, and lead to worse survival. Current approaches to manage these cancer-associated symptoms often work poorly, with most patients reporting a moderate to severe symptom burden. Therefore, there is an urgent need for treatments that improve these symptoms in patients with advanced pancreatic and colorectal cancer, and data suggests that medical cannabis can help. In this research study, we are examining the usefulness of using medical cannabis in patients with advanced pancreatic cancer and colorectal cancer to further study how cannabis can impact their symptom burden.",[318,319,320],"Pancreatic Cancer Non-resectable","Pancreatic Cancer Metastatic","Colorectal Cancer Metastatic",[322,323],"medical cannabis","patient-reported outcomes",{"date":325,"type":35},"2025-07-29",{"date":171,"type":35},{"date":173,"type":21},{"name":41,"class":42},{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":17,"minAge":336,"maxAge":337,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":340,"briefSummary":341,"conditions":342,"keywords":344,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":360},"100498085","geriatric-lateral-compression-1-pelvic-fractures-100498085","NCT05765669","Geriatric Lateral Compression 1 Pelvic Fractures","Percutaneous Screw Fixation for Operative Treatment Versus Non-Operative Treatment of Geriatric Lateral Compression 1 Pelvic Fractures - A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients \\>\u002F= 60 years of age\n* Lateral compression 1 pelvic ring fractures confirmed with plain radiographs, CT and\u002For MRI\n* Low energy mechanism of injury or an insufficiency fracture without a precipitating event\n* Acute injury within four weeks of presentation\n* Inability or significant pain to mobilize with physical therapy assistance for 48 hours: Significant pain as determined by a pain score ≥ 7 with the Visual Analogue Scale (VAS) after a Timed \"Up \\& Go\" (TUG) assessment, or inability to complete the TUG assessment.\n\nExclusion Criteria:\n\n* Dementia\n* Vertically or rotationally unstable pelvic ring injuries\n* Pathologic fracture secondary to tumor\n* Non-ambulatory prior to injury\n* Acute neurologic deficit\n* High-energy mechanism of injury\n* Concomitant injuries affecting ambulation\n* Presence of another injury or medical condition that prevents ambulation\n* Presence of implant or sacral morphology that prevents percutaneous sacral fixation\n* Enrollment in another research study the precludes co-enrollment\n* Likely problems, in the judgement of the investigators, with maintaining follow-up (i.e. patients with no fixed address, etc.)\n* Incarcerated or pending incarceration","60 Years","100 Years",{"count":339,"type":21},100,[24],"Lateral compression-1 (LC1) pelvic ring fragility fractures cause significant pain and morbidity. These fragility injuries are associated with prolonged immobility and long hospital stays. Currently there is no consensus on operative stabilization of LC1 pelvic fractures, nor are there evidence-based guidelines to aid in management of these injury types. Furthermore, there is variability in operative indications, improvement in pain and mobilization. The purpose of this study is to compare percutaneous screw fixation to non-operative management in symptomatic LC1 fragility fractures in elderly patients.",[343],"Lateral Compression 1 Pelvic Fracture",[345,346,347,348,349,350,351],"Lateral compression","Operative","Non-operative","Fragility fracture","Pelvic fracture","Percutaneous pelvis screw","Osteoporosis","2025-06-12",{"date":354,"type":35},"2025-06-13",{"date":356,"type":35},"2023-05-05",{"date":358,"type":21},"2026-09-30",{"name":41,"class":42},3,""]